Catechin [154-23-4]

Cat# HY-N0898-50mg

Size : 50mg

Brand : MedChemExpress

Contact local distributor :


Phone : +1 850 650 7790

Description

Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.

IC50 & Target[1]

COX-1

1.4 μM (IC50)

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
>10 μg/mL
Compound: page 1629, R25C1
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
[PMID: 17125236]
A549 ED50
>10 μg/mL
Compound: 46
Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay
Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay
[PMID: 1431932]
A549 IC50
>10 μg/mL
Compound: page 1629, R25C1
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
[PMID: 17125236]
Bel-7402 IC50
>10 μg/mL
Compound: page 1629, R25C1
Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
[PMID: 17125236]
BGC-823 IC50
>10 μg/mL
Compound: page 1629, R25C1
Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
[PMID: 17125236]
BMDC IC50
>50 μM
Compound: 16
Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
[PMID: 25769817]
BMDC IC50
>50 μM
Compound: 16
Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
[PMID: 25769817]
BMDC IC50
>50 μM
Compound: 16
Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
[PMID: 25769817]
BV-2 IC50
26.11 μM
Compound: 170
Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS induced NO production measured for 24 hrs by Griess reagent based analysis
Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS induced NO production measured for 24 hrs by Griess reagent based analysis
[PMID: 37683361]
BV-2 IC50
9.52 μM
Compound: 12
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
[PMID: 27623545]
H9 EC50
>345 μM
Compound: 20
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
[PMID: 8158164]
H9 IC50
>345 μM
Compound: 20
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
[PMID: 8158164]
HCT-8 ED50
>10 μg/mL
Compound: 46
Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay
Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay
[PMID: 1431932]
HCT-8 IC50
>10 μg/mL
Compound: page 1629, R25C1
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
[PMID: 17125236]
KB ED50
>10 μg/mL
Compound: 46
Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay
Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay
[PMID: 1431932]
MT4 CC50
86.8 μg/mL
Compound: 12
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 10425115]
MT4 IC50
>86.8 μg/mL
Compound: 12
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
[PMID: 10425115]
Platelet IC50
>50 μg/mL
Compound: (+)-Catechin
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
[PMID: 21106454]
Platelet IC50
27.65 μg/mL
Compound: (+)-Catechin
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
[PMID: 21106454]
TE-671 ED50
>10 μg/mL
Compound: 46
Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay
Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay
[PMID: 1431932]
In Vitro

Catechin ((+)-Catechin) exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM[1].
A dose-dependent reduction in color is observed after 24 hours of treatment with Catechin, and 54.76% of the cells are dead at the highest concentration of Catechin tested (160 μg/mL) whereas the IC50 of Catechin is achieved at 127.62 μg/mL Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL Catechin, respectively, undergo apoptosis. The expression levels of Caspase-3, -8, and -9 and p53 in MCF-7 cells treated with 150 μg/mL Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Animals treated with Catechin ((+)-Catechin) at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

290.27

Formula

C15H14O6

CAS No.
Appearance

Solid

Color

Yellow to brown

SMILES

O[C@@H]1[C@@H](C2=CC(O)=C(O)C=C2)OC3=CC(O)=CC(O)=C3C1

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (344.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 12.5 mg/mL (43.06 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4451 mL 17.2253 mL 34.4507 mL
5 mM 0.6890 mL 3.4451 mL 6.8901 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
331-21404-4
 20mg